Telix Pharmaceuticals Limited (TLX) reported a robust 24% year-over-year revenue growth for Q1 2026, reaching $230 million, and reaffirmed its full-year revenue guidance of $950 million to $970 million. Following this announcement, TLX shares surged 4.29% to $9.48 in after-hours trading. The company, known for its focus on precision medicine, is advancing several therapeutic candidates, including TLX591 for prostate cancer, which is currently in a Phase 3 trial.

This revenue uptick is largely attributed to strong performance in the Precision Medicine segment, particularly from its Illuccix and Gozellix products. The successful completion of Part 1 of the ProstACT Global trial for TLX591-Tx, which met its safety and tolerability objectives, further strengthens the company’s outlook. Additionally, Telix’s engagement with the FDA regarding its drug applications indicates a proactive approach to regulatory pathways.

For market professionals, the reaffirmation of revenue guidance and the positive clinical trial results suggest a solid growth trajectory for Telix, making it a stock to watch in the biotech sector.

Source: nasdaq.com